Activity of centrally acting and other drugs against tremor and hypothermia induced in mice by tremorine

A comparison of muscarinic cholinergic involvement in the antinociceptive effects of morphine and clonidine in the mouse

The antinociceptive effects (AE) of morphine and clonidine were examined in the mouse tail immersion test (48 degrees C). The interactions of these two agents with cholinergic (muscarinic) and anticholinergic (antimuscarinic) drugs were examined with respect to antinociceptive effect. Physostigmine, administered peripherally and intracerebroventricularly (i.c.v.) increased the AE of both morphine and clonidine. Atropine sulphate (but not atropine methylnitrate) antagonized the AE of both morphine and clonidine in a dose-dependent manner. Oxotremorine (OTMN) produced an AE that was additive with that of morphine and clonidine without being synergistic. These findings are discussed in terms of possible cholinergic mechanisms involved in the AEs produced by morpine and clonidine.

Anti-tremor action of C10Dichol, a peripheral acetylcholine synthesis inhibitor

1 Anti-tremor action of decamethylene bis-(hydroxyethyl)-dimethylammonium bromide (C10Dichol), a peripheral acetylcholine synthesis inhibitor, was investigated. 2 C10Dichol inhibited tremor induced by oxotremorine, nicotine and physostigmine and afforded partial protection from physostigmine-induced mortality in mice. 3 In non-paralysing doses, C10Dichol antagonized the neuromuscular effects of oxotremorine, nicotine and physostigmine. 4 Prior administration of C10Dichol failed to prevent tremor and neuromuscular paralysis induced by harmine and arecoline. 5 In the absence of any antimuscarinic property of C10Dichol, its neuromuscular effects appeared to be casually related to its anti-tremor action. 6 This study reveals a possibility for the development of peripherally acting anti-Parkinson drugs.

Peripheral and central muscarinic receptor affinity of psychotropic drugs

The muscarinic receptor affinity of 27 psychotropic and 5 anticholinergic substances was examined in 2 in-vivo and 2 in-vitro models. A highly significant correlation was obtained between the effect of all compounds examined on the atropine sensitive binding of 3H-PrBCM and the effect in the conventional guinea-pig ileum preparation. Antagonism of oxotremorine induced tremors in mice by anticholinergics and neuroleptics was also significantly correlated to the corresponding data obtained in the in-vitro tests. Due to very low potency in the physostigmine induced mortality test in mice too few ED50 values were obtained to perform statistical comparisons. It is concluded, that the conventional guinea-pig ileum model and the 3h-prBCM binding model are equally predictive as tests for antimuscarinic properties. When in-vivo anticholinergic data for neuroleptics are used it must be considered that a possible dopamine receptor blockade may diminish the antimuscarinic effect of the substance.

The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954

N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride (LON 954) causes a reproducible rest tremor in mice, of rapid onset and short duration with no associated rigidity or akinesia and in the absence of any marked changes in body temperature or accompanying peripheral parasympathomimetic effects. This tremor can be antagonised by the dopamine receptor agonists L-Dopa, bromocriptine, nomifensine and piribedil, as well as by anticholinergic anti-Parkinson drugs having an inhibitory effect on dopamine uptake such as benapryzine and benztropine. In contrast, benzhexol, orphenadrine and amantadine had no effect. LON 954 appears to be more specific than oxotremorine for the detection of drugs having therapeutic potential in the treatment of Parkinson's disease, particularly those exerting their effect through dopaminergic systems. An antagonist (BS 100-141), which is a structural isomer of LON 954, is also described.

Interaction of atropine or methylatropinium with four effects of two cholinergic drugs

In mice, pilocarpine - or oxotremorine - induced decrease in locomotor activity and increase of the reaction time to pain were antagonized by atropine and not by methylatropinium. Identical doses of atropine and methylatropinium suppressed the antagonism of the cholinergics towards reserpine-induced palpebral ptosis. Cholinergics-induced hypothermia was not clearly antagonized by atropine or methylatropinium.

Antioxotremorine action of propranolol

1. The influence of propranolol on the neuromuscular, tremor-producing and muscarinic effects of oxotremorine was examined. 2. In the isolated rat phrenic nerve-diaphragm preparation the neuromuscular blocking effect of oxotremorine was inhibited by propranolol in a dose-dependent manner. 3. Propranolol intensified the paralytic effect of tubocurarine in the rat diaphragm and prevented antagonism of tubocurarine paralysis by tetraethylammonium. 4. Propranolol was devoid of any curare-like effect in the isolated rectus abdominis muscle of the frog. 5. Vasodepressor responses to oxotremorine in rats and spasmogenic responses to oxotremorine in guinea-pig ileum were not antagonized by propranolol. 6. A dose-dependent antagonism of oxotremorine-induced tremor in mice was observed after pretreatment with propranolol and it is suggested that this effect is due to an antagonism of a presynaptic effect of oxotremorine at skeletal neuromuscular junctions.

The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug

Butaclamol hydrochloride (AY-23,028) is a member of a new chemical class for which antipsychotic activity in humans has recently been demonstrated. The compound antagonized amphetamine-induced stereotyped behavior in rats, amphetamine toxicity in aggregated mice and apomorphine-induced emesis in dogs. It depressed both discriminated avoidance and continuous lever-pressing behavior in rats and inhibited ambulation and rearing in the open field. At higher doses, AY-23,028 induced catalepsy. Adrenergic blocking activity, measured by the antagonism of epinephrine-induced mortality, was weak. These pharmacological actions are characteristic of neuroleptic drugs. In the dose range where the aforementioned effects were observed AY-23,028 did not antagonize either the tetrabenazine-induced ptosis or the tremorine syndrome and did not cause either hypothermia or ataxia. The potency and onset of action of AY-23,028 were comparable to those of fluphenazine but AY-23,028 was of longer duration. The results are discussed in relation to current concepts of neuroleptic mechanisms.

Tremor induced by tetrabenazine

1. Acute administration of tetrabenazine produced tremor in cats, in doses which caused sedation but not hypothermia.2. The pattern of movements resembled shivering rather than Parkinsonism, and warming the skin suppressed the tremor.3. The tremor was not influenced by hyoscine.4. Tremor produced by amylobarbitone was essentially similar to that induced by tetrabenazine.

The effect of anti-Parkinsonian drugs on oxotremorine-induced analgesia in mice

The antagonism of oxotremorine-induced analgesia in mice can be used to obtain a quantitative and objective assessment of the central anticholinergic activity of potential anti-Parkinsonian drugs.

The effects of tremorine and oxotremorine in hyperthyroid mice

Hyperthyroid mice exhibit only transient low-level tremor and hypothermia in response to tremorine and oxotremorine, yet the peripheral effects of these two agents are similar in intensity and duration to those elicited in control animals. These findings support the theory that tremor and hypothermia are both central effects and separate from the peripheral muscarinic actions of tremorine and oxotremorine. Of several possible explanations for the reduction in tremor and hypothermia, the most likely appears to be a potentiation of central adrenergic mechanisms in the hyperthyroid mice.